Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Exclusion Criteria

• •1. Patient had an adverse event in Study NS-065/NCNP-01-301 that, in the opinion of the investigator and/or the sponsor, precludes safe use of viltolarsen for the patient in this study;
• •2. Patient had a treatment which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NS-065/NCNP-01-301;
• •3. Patient took any other investigational drug(s) during or after completion of Study NS-065/NCNP-01-301;
• •4. Patient is judged by the investigator and/or the sponsor not to be appropriate to participate in the extension study for any reason.